Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase II clinical study of its KC1036 for adolescents aged 12 and above with advanced Ewing’s sarcoma (ES).
Drug Details
KC1036 is a Category 1.1 chemical drug and a tyrosine kinase inhibitor (TKI) targeting AXL, VEGFR2, and FLT3. Ewing’s sarcoma, the second most common primary malignant bone and soft tissue tumor in children and adolescents, typically affects those aged 10-20. The disease has a very poor prognosis, with an overall 5-year survival rate of less than 20%.
Clinical Trial
The Phase II study will assess the safety, efficacy, and pharmacokinetics of KC1036 in this patient population, aiming to provide new treatment options for a condition with limited therapeutic choices.-Fineline Info & Tech
